A body shape index (ABSI) is associated inversely with post-menopausal progesterone-receptor-negative breast cancer risk in a large European cohort.

Female Humans Middle Aged Body Mass Index Breast Neoplasms / complications Risk Factors Progesterone Prospective Studies Triple Negative Breast Neoplasms / complications Postmenopause Somatotypes

ABSI Body shape Breast cancer Hip size Obesity Waist size

Journal

BMC cancer

ISSN: 1471-2407

Titre abrégé: BMC Cancer

Pays: England

ID NLM: 100967800

Informations de publication

Date de publication:
19 Jun 2023

Historique:

received: 16 01 2023

accepted: 10 06 2023

medline: 21 6 2023

pubmed: 20 6 2023

entrez: 19 6 2023

Statut: epublish

Résumé

Associations of body shape with breast cancer risk, independent of body size, are unclear because waist and hip circumferences are correlated strongly positively with body mass index (BMI). We evaluated body shape with the allometric "a body shape index" (ABSI) and hip index (HI), which compare waist and hip circumferences, correspondingly, among individuals with the same weight and height. We examined associations of ABSI, HI, and BMI (per one standard deviation increment) with breast cancer overall, and according to menopausal status at baseline, age at diagnosis, and oestrogen and progesterone receptor status (ER+/-PR+/-) in multivariable Cox proportional hazards models using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 14.0 years, 9011 incident breast cancers were diagnosed among 218,276 women. Although there was little evidence for association of ABSI with breast cancer overall (hazard ratio HR = 0.984; 95% confidence interval: 0.961-1.007), we found borderline inverse associations for post-menopausal women (HR = 0.971; 0.942-1.000; n = 5268 cases) and breast cancers diagnosed at age ≥ 55 years (HR = 0.976; 0.951-1.002; n = 7043) and clear inverse associations for ER + PR- subtypes (HR = 0.894; 0.822-0.971; n = 726) and ER-PR- subtypes (HR = 0.906; 0.835-0.983 n = 759). There were no material associations with HI. BMI was associated strongly positively with breast cancer overall (HR = 1.074; 1.049-1.098), for post-menopausal women (HR = 1.117; 1.085-1.150), for cancers diagnosed at age ≥ 55 years (HR = 1.104; 1.076-1.132), and for ER + PR + subtypes (HR = 1.122; 1.080-1.165; n = 3101), but not for PR- subtypes. In the EPIC cohort, abdominal obesity evaluated with ABSI was not associated with breast cancer risk overall but was associated inversely with the risk of post-menopausal PR- breast cancer. Our findings require validation in other cohorts and with a larger number of PR- breast cancer cases.

Sections du résumé

BACKGROUND BACKGROUND

Associations of body shape with breast cancer risk, independent of body size, are unclear because waist and hip circumferences are correlated strongly positively with body mass index (BMI).

METHODS METHODS

We evaluated body shape with the allometric "a body shape index" (ABSI) and hip index (HI), which compare waist and hip circumferences, correspondingly, among individuals with the same weight and height. We examined associations of ABSI, HI, and BMI (per one standard deviation increment) with breast cancer overall, and according to menopausal status at baseline, age at diagnosis, and oestrogen and progesterone receptor status (ER+/-PR+/-) in multivariable Cox proportional hazards models using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.

RESULTS RESULTS

During a mean follow-up of 14.0 years, 9011 incident breast cancers were diagnosed among 218,276 women. Although there was little evidence for association of ABSI with breast cancer overall (hazard ratio HR = 0.984; 95% confidence interval: 0.961-1.007), we found borderline inverse associations for post-menopausal women (HR = 0.971; 0.942-1.000; n = 5268 cases) and breast cancers diagnosed at age ≥ 55 years (HR = 0.976; 0.951-1.002; n = 7043) and clear inverse associations for ER + PR- subtypes (HR = 0.894; 0.822-0.971; n = 726) and ER-PR- subtypes (HR = 0.906; 0.835-0.983 n = 759). There were no material associations with HI. BMI was associated strongly positively with breast cancer overall (HR = 1.074; 1.049-1.098), for post-menopausal women (HR = 1.117; 1.085-1.150), for cancers diagnosed at age ≥ 55 years (HR = 1.104; 1.076-1.132), and for ER + PR + subtypes (HR = 1.122; 1.080-1.165; n = 3101), but not for PR- subtypes.

CONCLUSIONS CONCLUSIONS

In the EPIC cohort, abdominal obesity evaluated with ABSI was not associated with breast cancer risk overall but was associated inversely with the risk of post-menopausal PR- breast cancer. Our findings require validation in other cohorts and with a larger number of PR- breast cancer cases.

Identifiants

DOI: 10.1186/s12885-023-11056-1 PMID: 37337133 PMC: PMC10278318

pubmed: 37337133

doi: 10.1186/s12885-023-11056-1

pii: 10.1186/s12885-023-11056-1

pmc: PMC10278318

doi:

Substances chimiques

Progesterone 4G7DS2Q64Y

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

562

Informations de copyright

Références

Biochim Biophys Acta. 2014 Mar;1842(3):473-81

pubmed: 23735216

EBioMedicine. 2019 Mar;41:526-537

pubmed: 30737086

Cancer Res. 2016 Mar 15;76(6):1653-63

pubmed: 26825173

Sci Rep. 2022 Jun 24;12(1):10774

pubmed: 35750890

Public Health Nutr. 2002 Dec;5(6B):1147-62

pubmed: 12639224

J Clin Endocrinol Metab. 1994 Feb;78(2):428-32

pubmed: 8106632

Br J Cancer. 2017 May 23;116(11):1486-1497

pubmed: 28441380

Biometrics. 1995 Jun;51(2):524-32

pubmed: 7662841

Cancer Biol Ther. 2015;16(3):484-92

pubmed: 25701261

Int J Cancer. 2015 Oct 1;137(7):1699-708

pubmed: 25810218

J Natl Cancer Inst. 2011 Feb 2;103(3):273-8

pubmed: 21163903

Mol Cell Biochem. 2016 Nov;422(1-2):109-120

pubmed: 27632388

Int J Cancer. 2017 Jun 15;140(12):2657-2666

pubmed: 28268252

Breast Cancer Res. 2020 May 1;22(1):39

pubmed: 32357907

J Obes. 2016;2016:8094275

pubmed: 27830087

Public Health Nutr. 2002 Aug;5(4):561-5

pubmed: 12186665

Cancer Res. 2011 Oct 15;71(20):6360-70

pubmed: 21868756

Int J Obes (Lond). 2012 Mar;36(3):431-9

pubmed: 21427693

Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):315-324

pubmed: 34853021

Breast Cancer Res. 2013;15(4):R68

pubmed: 23971947

Cancer Causes Control. 2022 Jul;33(7):971-981

pubmed: 35507195

Mol Cancer Res. 2016 Aug;14(8):707-19

pubmed: 27141101

Sci Rep. 2022 May 25;12(1):8812

pubmed: 35614088

N Engl J Med. 2016 Aug 25;375(8):794-8

pubmed: 27557308

Cancer Med. 2021 Aug;10(16):5614-5628

pubmed: 34196490

Obes Rev. 2016 Nov;17(11):1167-1177

pubmed: 27432212

Clin Cancer Res. 2018 Jul 15;24(14):3433-3446

pubmed: 29636357

Breast Cancer Res. 2019 Jul 24;21(1):82

pubmed: 31340854

Breast Cancer Res Treat. 2015 Apr;150(2):335-46

pubmed: 25762479

BMJ. 2017 Feb 28;356:j477

pubmed: 28246088

Breast Cancer Res. 2012 May 14;14(3):R76

pubmed: 22583394

Public Health Nutr. 2002 Dec;5(6B):1113-24

pubmed: 12639222

Sci Rep. 2020 Sep 3;10(1):14541

pubmed: 32883969

Cancer Causes Control. 2015 Feb;26(2):219-229

pubmed: 25430815

J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):9-25

pubmed: 26188694

Cancer Res. 2008 Sep 15;68(18):7386-93

pubmed: 18794126

Int J Cancer. 2021 Apr 1;148(7):1637-1651

pubmed: 33038275

Cancer. 2020 Aug 15;126(16):3638-3647

pubmed: 32530506

Cancer Med. 2022 Feb;11(4):1145-1159

pubmed: 35048536

BMC Cancer. 2021 Oct 15;21(1):1106

pubmed: 34654381

Proc Natl Acad Sci U S A. 1976 Dec;73(12):4536-40

pubmed: 1070004

BMC Med. 2021 Aug 2;19(1):186

pubmed: 34340701

J Cancer. 2020 Feb 10;11(9):2552-2559

pubmed: 32201525

PLoS One. 2012;7(7):e39504

pubmed: 22815707

Asian Pac J Cancer Prev. 2014;15(23):10245-50

pubmed: 25556455

Cancer Prev Res (Phila). 2011 Oct;4(10):1626-35

pubmed: 21813404

Breast Cancer Res Treat. 2009 Mar;114(2):287-99

pubmed: 18425577

Nucleic Acids Res. 2019 Nov 18;47(20):10645-10661

pubmed: 31598691